CM Life Sciences (CMLF) has a debt-to-equity ratio of 0.29, above the sector sector average of 0.2.
Get informed when a big investor buys or sells
+ Follow0.29
Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.
The latest debt-to-equity ratio for CMLF is 0.29. That is above the sector sector average of 0.2. Investors often review this figure alongside CM Life Sciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CMLF currently prints 0.29 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 43.9% above the sector mean. Large gaps often invite a closer look at CM Life Sciences's growth, margins, and balance sheet.
A debt-to-equity ratio of 0.29 for CM Life Sciences is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with CMLF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CMLF's debt-to-equity ratio (0.29), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.